Adagio Medical Holdings, Inc.
ADGM$0.94
+$0.48 (103.48%)+103.48%
OpenLoading chart...
IndexN/A
Market Cap0.02B
Enterprise Value0.02B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-0.61
P/S0.00
P/B1.39
P/C-0.89
EV/EBITDA-1.03
EV/SalesN/A
EPS (ttm)-1.53
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume426.56M
Shs Outstand0.02B
Change103.13%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $269.00K | $300.00K | $189.00K | $270.00K | $0.00 |
| Cost of Revenue | $1.94M | $1.31M | $875.00K | $1.16M | $0.00 |
| Gross Profit | $-1.67M | $-1.01M | $-686.00K | $-888.00K | $0.00 |
| Gross Margin | -620.07% | -335.33% | -362.96% | -328.89% | N/A |
| Operating Expenses | $60.81M | $26.94M | $23.23M | $19.76M | $13.54K |
| Operating Income | $-62.48M | $-27.94M | $-23.91M | $-20.64M | $-13.54K |
| Operating Margin | -23226.77% | -9314.00% | -12652.38% | -7646.30% | N/A |
| Net Income | $-53.76M | $-38.15M | $-23.67M | $-19.94M | $-13.54K |
| Net Margin | -19986.25% | -12715.33% | -12525.40% | -7384.44% | N/A |
| EPS (Basic) | $-3.54 | $-4.86 | $0.06 | $-0.34 | $-0.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA Systembusinesswire.com Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AIgurufocus.com Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardiabusinesswire.com Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progressbusinesswire.com Adagio Medical to Participate in the BofA Securities 2026 Health Care Conferencebusinesswire.com Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation Systembusinesswire.com Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Sees Large Growth in Short Interestdefenseworld.net Sensus Healthcare (NASDAQ:SRTS) versus Adagio Medical (NASDAQ:ADGM) Head to Head Contrastdefenseworld.net
Show 12 more stories
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conferencebusinesswire.com Short Interest in Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Rises By 60.0%defenseworld.net Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation Systembusinesswire.com Adagio Medical to Participate in the 25th Annual Needham Virtual Conferencebusinesswire.com Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026businesswire.com Adagio Medical Reports Fourth Quarter and Full Year 2025 Resultsbusinesswire.com Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheterbusinesswire.com Adagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature Ventricular Contractions (PVC)businesswire.com Adagio Medical to Participate in the 38th Annual Roth Conferencebusinesswire.com Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Short Interest Up 31.5% in Februarydefenseworld.net Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conferencebusinesswire.com New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardiabusinesswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Discover more
You may be interested in